Sign in or create an account to add this stock to your watchlist.
About Clovis Oncology (NASDAQ:CLVS)
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:CLVS
CUSIP18946410
Phone303-625-5000
Debt
Debt-to-Equity Ratio0.92
Current Ratio6.55
Quick Ratio5.74
Price-To-Earnings
Trailing P/E Ratio-9.71
Forward P/E Ratio-9.66
P/E GrowthN/A
Sales & Book Value
Annual Sales$55.51 million
Price / Sales47.09
Cash FlowN/A
Price / CashN/A
Book Value$7.50 per share
Price / Book6.63
Profitability
EPS (Most Recent Fiscal Year)($5.12)
Net Income$-346,390,000.00
Net Margins-545.80%
Return on Equity-79.02%
Return on Assets-33.90%
Miscellaneous
Employees360
Outstanding Shares52,550,000
Clovis Oncology (NASDAQ:CLVS) Frequently Asked Questions
What is Clovis Oncology's stock symbol?
Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."
How were Clovis Oncology's earnings last quarter?
Clovis Oncology (NASDAQ:CLVS) released its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing the consensus estimate of ($1.36) by $0.18. The biopharmaceutical company had revenue of $18.50 million for the quarter, compared to the consensus estimate of $18.34 million. Clovis Oncology had a negative return on equity of 79.02% and a negative net margin of 545.80%. The firm's revenue for the quarter was up 164.3% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.33) earnings per share. View Clovis Oncology's Earnings History.
When is Clovis Oncology's next earnings date?
What price target have analysts set for CLVS?
16 brokers have issued 1-year target prices for Clovis Oncology's shares. Their forecasts range from $50.00 to $125.00. On average, they expect Clovis Oncology's stock price to reach $87.04 in the next year. View Analyst Ratings for Clovis Oncology.
What are Wall Street analysts saying about Clovis Oncology stock?
Here are some recent quotes from research analysts about Clovis Oncology stock:
- 1. According to Zacks Investment Research, "Clovis’ Rubraca has not performed well in 2017 as it registered slower-than-expected sales. Nonetheless, Rubraca has bright prospects, given the tremendous demand for PARP inhibitors. Clovis is focused on continued approval for the drug. Rubraca is under review in EU for the same indication. A potential approval in Europe and in second-line setting in the United States will give a boost for the company. Several studies evaluating Rubraca in different types of ovarian cancer patients are ongoing. Clovis is looking for label expansion in second line or later maintenance treatment for advanced ovarian cancer. However, with just one approved product in the portfolio, Clovis is heavily dependent on Rubraca for growth, which concerns us. Clovis’ shares have underperformed the industry in the past six months. Loss estimates have narrowed ahead of Q1 results. Clovis has a mixed record of earnings surprises in the recent quarters." (5/1/2018)
- 2. Cann analysts commented, "The approval of the sNDA is in line with our expectations and supports our anticipated launch in this setting in Q2 2018. We estimate the impact of this approval will account for 56.7% of 2018 sales and will increase to 70.4% of sales in 2022. Therefore, our outlook remains unchanged." (4/8/2018)
- 3. JPMorgan Chase analysts commented, "2018 Procedure Growth Guidance Should Help Shares ISRG reported preliminary 4Q17 revenue of $892M (18% y/y), above our forecast of $865M and consensus’ estimates of $847M. Procedure growth of 17% came in higher than our 16.2% estimate and the Street’s 15.1% forecast. The sales breakout for 4Q included $457 in instrument revenue, $283 in system sales, and $153 for service, higher than our and Street estimates in each segment. 2018 guidance calls for 11-15% procedure growth, above our 10.9% forecast and in-line with consensus growth of 12.8%. This beat on revenue and procedure growth matched our expectations going into the report. Stellar revenue, strong procedure growth, and in-line 2018 guidance should boost shares today. There were 216 systems shipped in the quarter, well above our 180 unit estimate and the Street’s 187. Of these, 40 were shipped under operating lease agreements. However, implied system ASPs were $1.31M, below our modeled $1.55M and a more than $200Ksequential decline from Q3." (1/11/2018)
Who are some of Clovis Oncology's key competitors?
Some companies that are related to Clovis Oncology include BeiGene (BGNE), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Catalent (CTLT), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), GALAPAGOS NV/S (GLPG), Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR) and Taro Pharmaceutical Industries (TARO).
Who are Clovis Oncology's key executives?
Clovis Oncology's management team includes the folowing people:
- Mr. Patrick J. Mahaffy MA, Co-Founder, Chief Exec. Officer, Pres and Exec. Director (Age 55)
- Dr. Gillian C. Ivers-Read BSc, Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations (Age 64)
- Mr. Daniel W. Muehl CPA, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 54)
- Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance (Age 50)
- Mr. Corwin Dale Hooks, Chief Commercial Officer and Sr. VP (Age 51)
Has Clovis Oncology been receiving favorable news coverage?
Media stories about CLVS stock have been trending somewhat positive recently, according to Accern Sentiment. The research firm scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Clovis Oncology earned a news sentiment score of 0.01 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 46.12 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are Clovis Oncology's major shareholders?
Clovis Oncology's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Palo Alto Investors LP (7.53%), PointState Capital LP (4.84%), Franklin Resources Inc. (4.91%), Carmignac Gestion (2.87%), venBio Select Advisor LLC (2.22%) and Point72 Asset Management L.P. (2.20%). Company insiders that own Clovis Oncology stock include Gillian C Ivers-Read, James C Blair and Thorlef Spickschen. View Institutional Ownership Trends for Clovis Oncology.
Which major investors are selling Clovis Oncology stock?
CLVS stock was sold by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, PointState Capital LP, Franklin Resources Inc., Element Capital Management LLC, PNC Financial Services Group Inc., Wells Fargo & Company MN, C WorldWide Group Holding A S and Sector Gamma AS. Company insiders that have sold Clovis Oncology company stock in the last year include Gillian C Ivers-Read, James C Blair and Thorlef Spickschen. View Insider Buying and Selling for Clovis Oncology.
Which major investors are buying Clovis Oncology stock?
CLVS stock was acquired by a variety of institutional investors in the last quarter, including Palo Alto Investors LP, Summit Trail Advisors LLC, State of New Jersey Common Pension Fund D, Carmignac Gestion, Amundi Pioneer Asset Management Inc., Royal Bank of Canada, Trexquant Investment LP and Westfield Capital Management Co. LP. View Insider Buying and Selling for Clovis Oncology.
How do I buy shares of Clovis Oncology?
Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Clovis Oncology's stock price today?
One share of CLVS stock can currently be purchased for approximately $49.74.
How big of a company is Clovis Oncology?
Clovis Oncology has a market capitalization of $2.63 billion and generates $55.51 million in revenue each year. The biopharmaceutical company earns $-346,390,000.00 in net income (profit) each year or ($5.12) on an earnings per share basis. Clovis Oncology employs 360 workers across the globe.
How can I contact Clovis Oncology?
Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected]
MarketBeat Community Rating for Clovis Oncology (CLVS)
MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Vote "Outperform" if you believe CLVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Clovis Oncology (NASDAQ:CLVS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
16 Wall Street analysts have issued ratings and price targets for Clovis Oncology in the last 12 months. Their average twelve-month price target is $87.04, suggesting that the stock has a possible upside of 74.99%. The high price target for CLVS is $125.00 and the low price target for CLVS is $50.00. There are currently 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.75 | 2.75 | 2.65 | 2.61 |
| Ratings Breakdown: | 0 Sell Rating(s)
4 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
7 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $87.04 | $87.04 | $90.3077 | $85.4667 |
| Price Target Upside: | 74.99% upside | 52.03% upside | 64.41% upside | 30.50% upside |
Clovis Oncology (NASDAQ:CLVS) Consensus Price Target History
Clovis Oncology (NASDAQ:CLVS) Analyst Ratings History
Show:
(Data available from 5/21/2016 forward)
Clovis Oncology (NASDAQ:CLVS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Clovis Oncology (NASDAQ CLVS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 10.20%
Institutional Ownership Percentage: 94.13%
Clovis Oncology (NASDAQ CLVS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/9/2018 | Thorlef Spickschen | Director | Sell | 4,500 | $60.02 | $270,090.00 | 7,618 |  |
| 3/8/2018 | Thorlef Spickschen | Director | Sell | 4,500 | $61.47 | $276,615.00 | 12,118 | |
| 2/22/2018 | Thorlef Spickschen | Director | Sell | 4,500 | $60.00 | $270,000.00 | 16,618 | |
| 2/15/2018 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $54.09 | $162,270.00 | 180,571 | |
| 1/16/2018 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $59.16 | $177,480.00 | 183,571 | |
| 1/8/2018 | Thorlef Spickschen | Director | Sell | 4,500 | $64.97 | $292,365.00 | 21,118 | |
| 12/15/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $64.16 | $192,480.00 | 182,583 | |
| 12/8/2017 | Thorlef Spickschen | Director | Sell | 4,500 | $60.00 | $270,000.00 | 25,618 | |
| 11/15/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $63.70 | $191,100.00 | | |
| 10/16/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $84.54 | $253,620.00 | | |
| 9/15/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $69.50 | $208,500.00 | 191,583 | |
| 8/15/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $70.05 | $210,150.00 | 194,583 | |
| 8/4/2017 | James C Blair | Director | Sell | 18,450 | $78.61 | $1,450,354.50 | 2,185 | |
| 7/17/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $91.56 | $274,680.00 | 197,583 | |
| 6/15/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $61.82 | $185,460.00 | 200,583 | |
| 5/15/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $47.39 | $142,170.00 | 203,583 | |
| 4/17/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $56.02 | $168,060.00 | 206,583 | |
| 3/15/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $66.99 | $200,970.00 | 209,583 | |
| 11/2/2015 | Erle T. Mast | CFO | Sell | 3,000 | $105.56 | $316,680.00 | 135,583 | |
| 10/28/2015 | Lindsey Rolfe | insider | Sell | 4,000 | $98.02 | $392,080.00 | | |
| 10/15/2015 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $91.91 | $275,730.00 | 212,583 | |
| 10/5/2015 | Lindsey Rolfe | insider | Sell | 4,000 | $93.04 | $372,160.00 | | |
| 10/1/2015 | Erle T. Mast | CFO | Sell | 3,000 | $90.22 | $270,660.00 | 138,583 | |
| 9/18/2015 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $112.56 | $337,680.00 | 215,583 | |
| 9/1/2015 | Erle T. Mast | CFO | Sell | 3,000 | $79.51 | $238,530.00 | 141,583 | |
| 7/1/2015 | Erle T Mast | CFO | Sell | 3,000 | $85.70 | $257,100.00 | | |
| 6/1/2015 | Erle T Mast | CFO | Sell | 3,000 | $88.78 | $266,340.00 | | |
| 5/15/2015 | M James Barrett | Director | Sell | 2,424 | $92.43 | $224,050.32 | | |
| 4/1/2015 | Erle T Mast | CFO | Sell | 3,000 | $71.25 | $213,750.00 | | |
| 3/9/2015 | Erle T Mast | CFO | Sell | 9,000 | $78.84 | $709,560.00 | | |
| 3/5/2015 | James C Blair | Director | Sell | 8,528 | $77.70 | $662,625.60 | | |
| 1/16/2015 | Steven L Hoerter | Insider | Sell | 10,000 | $67.00 | $670,000.00 | | |
| 12/11/2013 | Erle Mast | CFO | Sell | 50,000 | $52.78 | $2,639,000.00 | 168,583 | |
| 12/5/2013 | Thorlef Spickschen | Director | Sell | 9,000 | $56.10 | $504,900.00 | 34,427 | |
| 6/5/2013 | Andrew R Allen | Insider | Sell | 22,594 | $68.54 | $1,548,592.76 | | |
| 6/4/2013 | M James Barrett | Director | Sell | 2,483 | $70.80 | $175,796.40 | | |
| 6/4/2013 | Parters Vii L P Domain | Major Shareholder | Sell | 159,192 | $64.58 | $10,280,619.36 | | |
| 6/4/2013 | Steven L Hoerter | Insider | Sell | 10,000 | $73.06 | $730,600.00 | | |
| 3/6/2013 | Parters Vii L P Domain | Major Shareholder | Sell | 250,000 | $24.59 | $6,147,500.00 | | |
| 8/16/2012 | Edward J Mckinley | Director | Buy | 9,701 | $15.50 | $150,365.50 | | |
(Data available from 1/1/2013 forward)
Clovis Oncology (NASDAQ CLVS) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Clovis Oncology (CLVS) Expected to Post Quarterly Sales of $31.34 Million
www.americanbankingnews.com - May 18 at 2:00 AM |
| Clovis Oncology (CLVS) Expected to Announce Earnings of -$1.43 Per Share
www.americanbankingnews.com - May 16 at 9:18 PM |
 | Clovis Oncology Announces Presentations at 2018 ASCO Annual Meeting
finance.yahoo.com - May 16 at 5:52 PM |
| How Lynparza Performed in 1Q18
finance.yahoo.com - May 14 at 8:18 AM |
| Clovis Oncology (CLVS) Forecasted to Post FY2018 Earnings of ($5.20) Per Share
www.americanbankingnews.com - May 14 at 3:46 AM |
| SunTrust Banks Analysts Increase Earnings Estimates for Clovis Oncology (CLVS)
www.americanbankingnews.com - May 14 at 2:36 AM |
| Clovis Oncology (CLVS) Upgraded to Sell by BidaskClub
www.americanbankingnews.com - May 12 at 4:23 PM |
| Clovis Oncology (CLVS) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 11 at 8:29 PM |
 | CORRECTING and REPLACING Clovis Oncology to Present at the Bank of America Merrill Lynch Healthcare ...
www.businesswire.com - May 11 at 6:07 PM |
| Oppenheimer Research Analysts Lower Earnings Estimates for Clovis Oncology (CLVS)
www.americanbankingnews.com - May 11 at 9:05 AM |
 | 3 Things In Biotech, May 10: AstraZeneca Expands, Roche Digs In, OncoSec Gets A Collab
seekingalpha.com - May 11 at 8:14 AM |
| Edited Transcript of CLVS earnings conference call or presentation 8-May-18 8:30pm GMT
finance.yahoo.com - May 10 at 8:17 AM |
| Clovis Oncology (CLVS) Releases Earnings Results
www.americanbankingnews.com - May 9 at 6:35 PM |
| Clovis (CLVS) Q1 Loss Wider Than Expected, Revenues Beat
finance.yahoo.com - May 9 at 5:41 PM |
| Clovis Oncology to Present at the Bank of America Merrill Lynch Healthcare Conference 2018
finance.yahoo.com - May 9 at 5:41 PM |
| Clovis Oncology's (CLVS) CEO Patrick Mahaffy on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 8:11 AM |
| Consolidated Research: 2018 Summary Expectations for Catalent, MGIC Investment, United Rentals, Clovis Oncology, Pure Storage, and Chipotle Mexican Grill — Fundamental Analysis, Key Performance Indications
finance.yahoo.com - May 9 at 8:11 AM |
| Clovis Oncology Announces First Quarter 2018 Operating Results
finance.yahoo.com - May 8 at 5:47 PM |
| How Has Clovis Oncology Inc’s (NASDAQ:CLVS) Earnings Fared Against The Long Term Trend
finance.yahoo.com - May 8 at 5:47 PM |
| Clovis: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 5:47 PM |
| Clovis Oncology (CLVS) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 3 at 10:17 AM |
| Is Clovis Oncology Inc’s (NASDAQ:CLVS) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - May 1 at 5:22 PM |
| Clovis Oncology (CLVS) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - May 1 at 12:26 PM |
| Clovis Oncology (CLVS) Expected to Announce Quarterly Sales of $17.50 Million
www.americanbankingnews.com - May 1 at 3:50 AM |
| Clovis Oncology (CLVS) Expected to Post Earnings of -$1.34 Per Share
www.americanbankingnews.com - April 29 at 7:58 AM |
| BidaskClub Lowers Clovis Oncology (CLVS) to Strong Sell
www.americanbankingnews.com - April 27 at 12:13 PM |
| Clovis Oncology (CLVS) Given a $86.00 Price Target by Credit Suisse Group Analysts
www.americanbankingnews.com - April 27 at 10:36 AM |
| Clovis Oncology to Announce First Quarter 2018 Financial Results and Host Webcast Conference Call on May 8
finance.yahoo.com - April 24 at 5:40 PM |
| Clovis Oncology (CLVS) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - April 24 at 7:28 AM |
| Bank of America Lowers Clovis Oncology (CLVS) Price Target to $75.00
www.americanbankingnews.com - April 20 at 8:00 PM |
| Clovis Oncology (CLVS) Stock Rating Reaffirmed by Morgan Stanley
www.americanbankingnews.com - April 20 at 8:00 PM |
| Clovis Oncology (CLVS) Earns "Neutral" Rating from Goldman Sachs
www.americanbankingnews.com - April 20 at 8:00 PM |
| Zacks Investment Research Upgrades Clovis Oncology (CLVS) to "Hold"
www.americanbankingnews.com - April 19 at 12:49 PM |
| Clovis Oncology (CLVS) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - April 19 at 11:20 AM |
| Zacks Investment Research Upgrades Clovis Oncology (CLVS) to "Buy"
www.americanbankingnews.com - April 18 at 7:30 PM |
| ValuEngine Downgrades Clovis Oncology (CLVS) to Sell
www.americanbankingnews.com - April 17 at 11:05 AM |
| Clovis prices equity and convertible debt offerings
seekingalpha.com - April 17 at 8:21 AM |
| Today’s Research Reports on Stocks to Watch: Clovis Oncology and Loxo Oncology
finance.yahoo.com - April 17 at 8:21 AM |
 | Clovis Oncology (CLVS) Announces Offerings of Convertible Senior Notes and Common Stock
www.streetinsider.com - April 16 at 8:10 AM |
| Clovis Oncology Announces Proposed Offerings of Convertible Senior Notes and Common Stock
finance.yahoo.com - April 16 at 8:10 AM |
| Clovis Oncology's (CLVS) Overweight Rating Reiterated at JPMorgan Chase
www.americanbankingnews.com - April 14 at 3:07 PM |
| Clovis Oncology (CLVS) Raised to "Strong-Buy" at BidaskClub
www.americanbankingnews.com - April 14 at 8:28 AM |
| Clovis Oncology (CLVS) Receives Buy Rating from Bank of America
www.americanbankingnews.com - April 13 at 6:01 PM |
| -$1.34 Earnings Per Share Expected for Clovis Oncology (CLVS) This Quarter
www.americanbankingnews.com - April 12 at 9:19 AM |
| Clovis Oncology (CLVS) Downgraded to "Buy" at BidaskClub
www.americanbankingnews.com - April 11 at 10:10 PM |
| Clovis Oncology's (CLVS) "Overweight" Rating Reiterated at Morgan Stanley
www.americanbankingnews.com - April 11 at 5:35 PM |
| ValuEngine Upgrades Clovis Oncology (CLVS) to "Hold"
www.americanbankingnews.com - April 11 at 12:37 PM |
| Clovis Oncology (CLVS) Upgraded to Hold by BidaskClub
www.americanbankingnews.com - April 11 at 11:30 AM |
| 2 Biotech Stocks Whose Rallies Should Continue
seekingalpha.com - April 10 at 8:17 AM |
| 3 Things In Biotech, April 9: Clovis Hunts Anew, Conatus Falters, Newlink Soul Searches
seekingalpha.com - April 10 at 8:17 AM |
Clovis Oncology (NASDAQ:CLVS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Clovis Oncology (NASDAQ:CLVS) Income Statement, Balance Sheet and Cash Flow Statement
Clovis Oncology (NASDAQ CLVS) Stock Chart for Monday, May, 21, 2018
Loading chart…
